Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

News Center

6756758(2)-91.jpg

LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform Development

Learn More

All

2025

2024

2023

2022

2021

2020

LaNova Medicines Announces IND Approval of LM-350 by NMPA

2025-11-17

Learn More
LaNova Medicines Announces First Patient Dosed in Phase I Clinical Trial of LM-350 in Australia

2025-09-29

Learn More
LaNova Medicines Announces First Patient Dosed in Phase I Clinical Trial of LM-2417

2025-09-23

Learn More
LaNova Medicines Receives CDE Approval to Initiate Phase II Trial of LM-24C5 (Anti-CEACAM5/4-1BB BsAb)

2025-08-07

Learn More
LaNova Medicines Receives FDA IND Clearance for LM-350, a Novel CDH17-Targeting ADC

2025-07-24

Learn More
CDE Granted LM-108 Breakthrough Therapy Designation for 2L CCR8-Positive G/GEJ Adenocarcinomas

2025-06-26

Learn More

1